Autologous Stem Cells in the Management of Fistulating Perianal Crohn's Disease

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorOxford University Hospitals NHS Trust

About this trial

Crohn's disease is a chronic inflammatory condition that can affect any part of the bowel which can be controlled by a combination of medical and surgical treatments but cannot be cured. A 1/3 of patients have involvement of the perianal region. There are several conditions that can affect the perianal region but the most debilitating is the presence of fistulating disease. Fistulae are small tunnels that run under the skin from the inside of the anus to skin outside the anus and are associated with the inflammatory process seen with Crohn's disease. They can cause pain, infection and discharge which adversely affects the quality of life of the patient. Surgery can be used to treat the symptoms however cure is often difficult to achieve.

Stem cells have anti-inflammatory potential and have been shown to be a useful treatment for this condition in combination with effective medical therapy. The stem cells used in the studies need to be prepared 48 hours before use which limits their usage and this is not readily available in the UK.

The proposed study aims to assess the feasibility of using autologous stem cells prepared with a rapid preparation system at the time of surgery, within the operating room (currently in use at Oxford University Hospitals NHS Foundation Trust (OUH) within the orthopaedic department for a different indication) for fistulating anal Crohn's disease. The stem cells are derived from the patients own bone marrow. The patients undergoing surgery would be having it done for the stem cell treatment. They will then undergo 3 follow up visits and complete questionnaires at each visit alongside a clinical assessment. This study is funded by Occtopus (Colorectal charity based in Oxford).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosed with perianal Crohn's disease

Medically controlled proximal disease as confirmed by endoscopy or Harvey Bradshaw Index scores of less than 7 (remission / mild disease)

Recent MRI scan to assess fistulating perianal Crohn's

Non-branching fistula with no more than 1 internal opening and 2 external opening i.e. a single tract.

Disqualifiers

Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.

Participants who have participated in another research trial involving an investigational product in the past 12 weeks.

Ongoing perianal sepsis or anal stenosis

Patients with a defunctioning stoma

Trial design

Design model

Single group

Treatments tested in this trial

  • Harvest and injection of stem cells

    Device

    Stem cells will be harvested from bone marrow aspirate and injected into the fistula tract The stem cells are the device intervention for this trial and we are looking to assess the procedure of harvesting and injecting the stem cells Patients will undergo study questionnaire: Harvey-Bradshaw Index, perianal Crohn's disease activity index, and Short IBD questionnaire will be administered before surgery and then at 6 weeks, 3 and 6 months after stem cell intervention.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Injection of stem cell into fistulating perianal Crohn's diseaseExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Feasibility of using autologous mesenchymal stem cells in the management of fistulating perianal Crohn's disease.

Operative time and difficulties encountered intraoperatively will be documented on the operation note. Subjective impression of the operating surgeon alongside feedback from the nursing team in theatre will help assess the procedure. Feedback from the operative team will be documented on the WHO checklist (where a section for feedback exists).

Time frame
During surgery

Secondary outcomes

1

Safety of stem cell treatment

patient reported adverse effects and clinical assessment

Time frame
after surgery for 6 months with clinical review at 6 weeks, 3 months and 6 months
2

Safety of stem cell treatment

Changes in Quality of life or Disease activity scores (monitored by perianal Crohn's disease activity index, Harvey-Bradshaw Index, and Short IBD questionnaires)

Time frame
after surgery for 6 months with clinical review at 6 weeks, 3 months and 6 months
3

Safety of stem cell treatment

Attendance to Emergency department

Time frame
after surgery for 6 months with clinical review at 6 weeks, 3 months and 6 months
4

Safety of stem cell treatment

Contact with IBD nurse specialists

Time frame
after surgery for 6 months with clinical review at 6 weeks, 3 months and 6 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: